查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1768522

伽瑪刀全球市場

Gamma Knife
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球伽瑪刀市場規模將達到 4.039 億美元

全球伽瑪刀市場規模預計在2024年為3.108億美元，到2030年將達到4.039億美元，在2024-2030年的分析期間內，複合年成長率為4.5%。作為本報告分析的細分市場之一，惡性腫瘤市場預計將以4.7%的複合年成長率成長，到分析期結束時達到2.211億美元。良性腫瘤市場的複合年成長率預計在分析期間為4.4%。

美國市場規模估計為 8,220 萬美元，中國市場預計複合年成長率為 6.9%

美國伽瑪刀市場規模預計2024年達到8,220萬美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到8,730萬美元，在2024-2030年的分析期內，複合年成長率為6.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為2.9%和3.7%。在歐洲，預計德國市場的複合年成長率為3.4%。

全球伽瑪刀市場－定義、關鍵趨勢與促進因素摘要

什麼是伽瑪刀？為什麼它在現代神經外科中如此重要？

伽瑪刀是一種立體定位放射放射線手術(SRS) 手術，用於治療腦腫瘤、血管畸形和其他神經系統疾病，且無需侵入性手術。但為什麼伽瑪刀被認為是神經外科領域的突破性治療方法呢？與傳統手術不同，伽瑪刀使用聚焦的伽瑪射線束精準瞄準異常腦組織，並在不損害周圍健康組織的情況下釋放高劑量輻射。這種非侵入性手術以其精準、有效和快速恢復而聞名，使其成為腦轉移瘤、動靜脈畸形 (AVM)、三叉神經痛以及某些良性和惡性腦腫瘤患者的首選治療方案。由於伽瑪刀無需物理切口，它可以最大限度地降低傳統腦外科手術的風險，例如感染、出血和較長的恢復時間。隨著對微創治療的需求日益成長，伽瑪刀技術因其能夠精準治療複雜的腦部疾病且副作用極小，在現代神經外科中的重要性日益凸顯。

科技進步如何影響伽瑪刀市場？

技術創新在伽瑪刀系統的進步中發揮了關鍵作用。但這些進步是如何提高治療的有效性和安全性的呢？一項重大進展是將核磁共振和電腦斷層掃描等先進成像技術與伽瑪刀系統相結合，從而改善了治療計劃並提高了治療精度。這些影像技術可以更精確地定位腦部病變，使放射線能夠準確地輸送到所需的位置，最大限度地減少對健康組織的損傷。此外，即時影像處理和3D治療計劃軟體的引入提高了劑量傳輸的準確性，從而可以更有針對性地治療腦轉移瘤和動靜脈畸形（AVM）等疾病。

另一項重要的創新是伽瑪刀技術本身的演進。最新版本的伽瑪刀系統，例如Icon伽瑪刀，配備了先進的運動追蹤和固定系統，可實現無框架治療，減輕患者不適，並擴大了治療範圍。此外，新系統採用分次照射，這意味著可以根據需要分次進行放射治療，從而為治療更大或更複雜的病灶提供了更大的靈活性。

這些技術進步使得伽瑪刀治療更安全、更舒適、更有效，幫助醫療保健提供者擴大放射線手術在更廣泛的神經系統疾病的應用。

監管和醫療保健趨勢如何影響伽瑪刀市場？

法律規範和醫療保健趨勢在塑造伽瑪刀市場方面發揮什麼作用？美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構在確保伽瑪刀技術的安全性和有效性方面發揮關鍵作用。嚴格的監管標準指導著伽瑪刀系統等醫療設備的核准和使用，確保這些治療符合安全要求並提供一致的高品質護理。此外，醫療保健提供者必須遵守輻射安全標準，隨著立體定位放射線手術在全球的推廣，這一點變得越來越重要。

日益成長的價值導向型醫療保健趨勢也影響著伽瑪刀技術的普及。隨著醫療保健體系轉向以結果為導向的模式，像伽瑪刀這樣精準度高、副作用少、恢復時間短的治療方法，對患者和醫療服務提供者都越來越有吸引力。與需要較長住院時間和復原時間的傳統開放性手術相比，非侵入性手術更具成本效益，促使更多醫院和診所投資伽瑪刀技術。此外，對微創手術日益成長的需求正在推動全球立體定位放射線手術中心的擴張，尤其是在亞太和拉丁美洲等地區。

此外，全球癌症發生率（尤其是腦轉移瘤）的上升預計將推動對伽瑪刀等先進放射外科工具的需求。這些監管和醫療保健趨勢正在塑造市場，確保伽瑪刀仍然是治療複雜腦部疾病的安全、有效且經濟可行的選擇。

推動伽瑪刀市場成長的關鍵因素有哪些？

伽瑪刀市場的成長受到幾個關鍵因素的推動，包括腦部疾病盛行率的上升、放射外科技術的進步以及對微創治療方案的需求不斷成長。主要促進因素之一是腦腫瘤、血管畸形和神經病變的盛行率上升，這推動了對精確有效治療方法的需求。伽瑪刀放射放射線手術因其能夠以最小的風險治療這些疾病而廣受認可，使其成為不適合傳統手術的患者的首選。影像和放射技術的進步提高了伽瑪刀治療的準確性和安全性，這也是一個主要促進因素。這些技術創新使醫療保健提供者能夠治療更複雜的病例，改善患者的治療效果，並減少副作用。此外，人口老化也促進了伽瑪刀市場的成長，因為老年患者通常患腦部疾病的風險更高，並且更傾向於尋求非侵入性治療。

隨著患者和醫療保健提供者尋求恢復更快、併發症更少的治療方法，對門診治療的需求也在上升。伽瑪刀治療通常不需要住院過夜，這使其成為門診病人的理想選擇。全球伽瑪刀中心的數量不斷增加，尤其是在新興市場，隨著越來越多的醫療保健提供者投資這項最尖端科技，這進一步推動了市場擴張。對非侵入性治療的需求不斷成長、技術進步以及神經系統疾病負擔的增加，推動全球伽瑪刀市場強勁成長，使其成為未來神經外科的關鍵工具。

部分

適應症（惡性腫瘤、良性腫瘤、血管性疾病、功能性疾病、眼科疾病）

受訪公司範例

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP21871

Global Gamma Knife Market to Reach US$403.9 Million by 2030

The global market for Gamma Knife estimated at US$310.8 Million in the year 2024, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Malignant Tumors, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.2 Million While China is Forecast to Grow at 6.9% CAGR

The Gamma Knife market in the U.S. is estimated at US$82.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Gamma Knife Market - Definition, Key Trends & Drivers Summarized

What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?

Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery-such as infection, bleeding, and extended recovery-are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.

How Are Technological Advancements Shaping the Gamma Knife Market?

Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.

Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.

These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.

How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?

What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.

The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times-such as Gamma Knife-are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.

Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.

What Are the Key Drivers Behind the Growth of the Gamma Knife Market?

The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.

The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors-rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases-are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.

SCOPE OF STUDY:

The report analyzes the Gamma Knife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Gamma Knife - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Brain Tumors and Neurological Disorders Drives Demand for Gamma Knife Radiosurgery
    • Technological Advancements in Gamma Knife Systems Propel Growth in Precision Treatment for Complex Brain Conditions
    • Increasing Adoption of Non-Invasive Treatment Solutions Expands Market for Gamma Knife as a Preferred Alternative to Traditional Surgery
    • Growing Focus on Minimally Invasive Neurosurgery Fuels Demand for Gamma Knife in the Treatment of Brain Metastases and Arteriovenous Malformations (AVMs)
    • Rising Demand for Outpatient Treatment Options Strengthens the Business Case for Gamma Knife Radiosurgery Due to Shorter Recovery Times
    • Increasing Use of Gamma Knife for Treating Functional Disorders, Such as Trigeminal Neuralgia, Expands Clinical Applications
    • Technological Innovations in Imaging and Targeting Techniques Propel Growth in Real-Time Monitoring and Enhanced Treatment Accuracy
    • Rising Global Awareness of Stereotactic Radiosurgery (SRS) Strengthens Market Demand for Gamma Knife in Neurological and Oncological Treatments
    • Growing Emphasis on Reducing Side Effects and Enhancing Patient Outcomes Fuels Adoption of Gamma Knife for High-Precision Radiosurgery
    • Increasing Focus on Elderly Patients and Their Unique Treatment Needs Expands Market for Gamma Knife as a Safe and Effective Option
    • Technological Advancements in Motion Tracking and Immobilization Systems Support Growth in Frameless Gamma Knife Treatments
    • Rising Adoption of Gamma Knife in Pediatric Neurosurgery Expands Market for Non-Invasive Treatment of Pediatric Brain Disorders
    • Growing Focus on Value-Based Healthcare Drives Adoption of Gamma Knife as a Cost-Effective Alternative to Open Surgery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Malignant Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Benign Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Vascular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Functional Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Ocular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Gamma Knife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Japan 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: China 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: France 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Germany 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Italy 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: UK 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Spain 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Russia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Australia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: India 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: South Korea 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Argentina 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Brazil 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Mexico 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Iran 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Israel 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UAE 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Africa 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION